Efficacy and safety study, in collaboration with MD Anderson Cancer Center,
will assess BL-8040 as combination treatment with immunosuppressants
Interim results of study, in patients with hypoplastic myelodysplastic
syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016“